{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:03:48Z","timestamp":1790247828510,"version":"4.1.0"},"reference-count":204,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008736","name":"Fondo de Fomento al Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["17I10095"],"award-info":[{"award-number":["17I10095"]}],"id":[{"id":"10.13039\/501100008736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Iron chelation has been introduced as a new therapeutic concept for the treatment of neurodegenerative diseases with features of iron overload. At difference with iron chelators used in systemic diseases, effective chelators for the treatment of neurodegenerative diseases must cross the blood\u2013brain barrier. Given the promissory but still inconclusive results obtained in clinical trials of iron chelation therapy, it is reasonable to postulate that new compounds with properties that extend beyond chelation should significantly improve these results. Desirable properties of a new generation of chelators include mitochondrial destination, the center of iron-reactive oxygen species interaction, and the ability to quench free radicals produced by the Fenton reaction. In addition, these chelators should have moderate iron binding affinity, sufficient to chelate excessive increments of the labile iron pool, estimated in the micromolar range, but not high enough to disrupt physiological iron homeostasis. Moreover, candidate chelators should have selectivity for the targeted neuronal type, to lessen unwanted secondary effects during long-term treatment. Here, on the basis of a number of clinical trials, we discuss critically the current situation of iron chelation therapy for the treatment of neurodegenerative diseases with an iron accumulation component. The list includes Parkinson\u2019s disease, Friedreich\u2019s ataxia, pantothenate kinase-associated neurodegeneration, Huntington disease and Alzheimer\u2019s disease. We also review the upsurge of new multifunctional iron chelators that in the future may replace the conventional types as therapeutic agents for the treatment of neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ph11040109","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T10:08:02Z","timestamp":1539943682000},"page":"109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-8570","authenticated-orcid":false,"given":"Marco T.","family":"Nu\u00f1ez","sequence":"first","affiliation":[{"name":"Faculty of Sciences, Universidad de Chile, Las Palmeras 3425, Santiago 7800024, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Chana-Cuevas","sequence":"additional","affiliation":[{"name":"Center for the Treatment of Movement Disorders, Universidad de Santiago de Chile, Belisario Prat 1597, Santiago 83800000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1471-4159.1958.tb12607.x","article-title":"The effect of age on the non-haemin iron in the human brain","volume":"3","author":"Hallgren","year":"1958","journal-title":"J. Neurochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","article-title":"Iron, brain ageing and neurodegenerative disorders","volume":"5","author":"Zecca","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00702-010-0470-z","article-title":"Brain iron metabolism and its perturbation in neurological diseases","volume":"118","author":"Crichton","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1532-5415.1983.tb03712.x","article-title":"Iron status and anemia in the elderly: New findings and a review of previous studies","volume":"31","author":"Garry","year":"1983","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10534-012-9523-0","article-title":"Iron toxicity in neurodegeneration","volume":"25","author":"Nunez","year":"2012","journal-title":"Biometals"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1515\/revneuro-2017-0020","article-title":"Iron in neurodegenerative disorders: Being in the wrong place at the wrong time?","volume":"28","author":"Apostolakis","year":"2017","journal-title":"Rev. Neurosci."},{"key":"ref_8","first-page":"7049108","article-title":"Parkinson\u2019s Disease: The Mitochondria-Iron Link","volume":"2016","author":"Munoz","year":"2016","journal-title":"Parkinson Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Carocci, A., Catalano, A., Sinicropi, M.S., and Genchi, G. (2018). Oxidative stress and neurodegeneration: The involvement of iron. Biometals.","DOI":"10.1007\/s10534-018-0126-2"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2741\/s498","article-title":"New targeted therapies and diagnostic methods for iron overload diseases","volume":"10","author":"Kolnagou","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S13065","article-title":"Management of transfusional iron overload\u2014Differential properties and efficacy of iron chelating agents","volume":"2","author":"Kwiatkowski","year":"2011","journal-title":"J. Blood Med."},{"key":"ref_12","first-page":"411","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali","year":"2012","journal-title":"Blood Transfus."},{"key":"ref_13","first-page":"197","article-title":"Iron chelation therapy in transfusion-dependent thalassemia patients: Current strategies and future directions","volume":"6","author":"Saliba","year":"2015","journal-title":"J. Blood Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jtemb.2012.03.009","article-title":"Iron mobilization using chelation and phlebotomy","volume":"26","author":"Flaten","year":"2012","journal-title":"J. Trace Elem. Med. Boil."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.1984.tb06096.x","article-title":"Depletion of excessive liver iron stores with desferrioxamine","volume":"58","author":"Cohen","year":"1984","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s00415-013-6951-x","article-title":"Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy","volume":"260","author":"Lee","year":"2013","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0404.1989.tb01782.x","article-title":"Is Parkinson\u2019s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?","volume":"126","author":"Youdim","year":"1989","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s100720300036","article-title":"Differential diagnosis of Parkinson\u2019s disease and atypical parkinsonian disorders by magnetic resonance imaging","volume":"24","author":"Savoiardo","year":"2003","journal-title":"Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2017.09.020","article-title":"Brain regional iron contents in progressive supranuclear palsy","volume":"45","author":"Lee","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxrep.2017.03.005","article-title":"Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients","volume":"4","author":"Fernandez","year":"2017","journal-title":"Toxicol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ene.13208","article-title":"Motor associations of iron accumulation in deep grey matter nuclei in Parkinson\u2019s disease: A cross-sectional study of iron-related magnetic resonance imaging susceptibility","volume":"24","author":"Loane","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archneur.56.5.569","article-title":"Increased basal ganglia iron levels in Huntington disease","volume":"56","author":"Bartzokis","year":"1999","journal-title":"Arch. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","article-title":"Iron accumulation in Alzheimer disease is a source of redox-generated free radicals","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1020731021276","article-title":"Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease","volume":"16","author":"Perry","year":"2003","journal-title":"Biometals"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.3233\/JAD-179944","article-title":"Iron and Alzheimer\u2019s Disease: An Update on Emerging Mechanisms","volume":"64","author":"Lane","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/archpsyc.57.1.47","article-title":"In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging","volume":"57","author":"Bartzokis","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neurobiolaging.2017.10.017","article-title":"Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early- and late-onset Alzheimer\u2019s disease","volume":"62","author":"Bulk","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1042\/CS20160072","article-title":"Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich\u2019s ataxia","volume":"130","author":"Chiang","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00062-011-0127-9","article-title":"Involvement of globus pallidus and midbrain nuclei in pantothenate kinase-associated neurodegeneration: Measurement of T2 and T2* time","volume":"23","author":"Speckter","year":"2013","journal-title":"Clin. Neuroradiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.braindev.2011.09.010","article-title":"Early-onset neurodegeneration with brain iron accumulation due to PANK2 mutation","volume":"34","author":"Rossi","year":"2012","journal-title":"Brain Dev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archneur.1991.00530240091029","article-title":"Hallervorden-Spatz syndrome and brain iron metabolism","volume":"48","author":"Swaiman","year":"1991","journal-title":"Arch. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/B978-0-444-63233-3.00019-1","article-title":"Neurodegeneration with brain iron accumulation","volume":"147","author":"Hayflick","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pjnns.2014.05.001","article-title":"Update on neurodegeneration with brain iron accumulation","volume":"48","author":"Kozubski","year":"2014","journal-title":"Neurol. I Neurochir. Polska"},{"key":"ref_34","first-page":"1","article-title":"Neurodegeneration with brain iron accumulation: An overview","volume":"8","author":"Tonekaboni","year":"2014","journal-title":"Iran. J. Child Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-12-802395-2.00011-0","article-title":"Neurodegeneration with brain iron accumulation","volume":"145","author":"Wiethoff","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.27275","article-title":"Iron as a therapeutic target for Parkinson\u2019s disease","volume":"33","author":"Moreau","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/ajcn\/44.4.468","article-title":"Impaired phenylalanine-tyrosine conversion in patients with iron-deficiency anemia studied by a L-(2H5)phenylalanine-loading test","volume":"44","author":"Lehmann","year":"1986","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0005-2728(98)00027-9","article-title":"Iron-sulfur clusters\/semiquinones in complex I","volume":"1364","author":"Ohnishi","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_39","first-page":"1066","article-title":"Iron-Sulfur Clusters in Mitochondrial Metabolism: Multifaceted Roles of a Simple Cofactor","volume":"81","author":"Stiban","year":"2016","journal-title":"Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-4165(98)00036-1","article-title":"Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects","volume":"1381","author":"Metodiewa","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.nbd.2004.03.014","article-title":"On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: Mitochondria damage, necrosis, and hydroxyl radical formation","volume":"16","author":"Arriagada","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1074\/jbc.M500657200","article-title":"Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: Stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease","volume":"280","author":"Zoccarato","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2850341","DOI":"10.1155\/2018\/2850341","article-title":"Unraveling the Burden of Iron in Neurodegeneration: Intersections with Amyloid Beta Peptide Pathology","volume":"2018","author":"Uranga","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Salazar, J., Mena, N., and N\u00fa\u00f1ez, M.T. (2006). Iron dyshomeostasis in Parkinson\u2019s disease. J. Neural Transm. Suppl., 205\u2013213.","DOI":"10.1007\/978-3-211-33328-0_22"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2011.04.137","article-title":"Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity","volume":"409","author":"Mena","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Urrutia, P.J., Aguirre, P., Tapia, V., Carrasco, C.M., Mena, N.P., and Nunez, M.T. (2017). Cell death induced by mitochondrial complex I inhibition is mediated by Iron Regulatory Protein 1. Biochim. Biophys. Acta.","DOI":"10.1016\/j.bbadis.2017.05.015"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/152308603322110904","article-title":"alpha-synuclein aggregation: A link between mitochondrial defects and Parkinson\u2019s disease?","volume":"5","author":"Lee","year":"2003","journal-title":"Antioxid. Redox Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.12.003","article-title":"Intersecting pathways to neurodegeneration in Parkinson\u2019s disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system","volume":"22","author":"Betarbet","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"ref_49","first-page":"693761","article-title":"Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD","volume":"2011","author":"Esteves","year":"2011","journal-title":"Parkinson Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1007\/s12035-016-0104-z","article-title":"Low-Intensity Ultrasound Decreases alpha-Synuclein Aggregation via Attenuation of Mitochondrial Reactive Oxygen Species in MPP(+)-Treated PC12 Cells","volume":"54","author":"Karmacharya","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1385\/NMM:4:1-2:21","article-title":"Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"4","author":"Hashimoto","year":"2003","journal-title":"Neuromol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1820","DOI":"10.1038\/cddis.2015.166","article-title":"Aggregated alpha-synuclein and complex I deficiency: Exploration of their relationship in differentiated neurons","volume":"6","author":"Reeve","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2017.04.004","article-title":"Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson\u2019s disease","volume":"109","author":"Rocha","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., and Bellucci, A. (2017). Mitochondria and alpha-Synuclein: Friends or Foes in the Pathogenesis of Parkinson\u2019s Disease?. Genes, 8.","DOI":"10.3390\/genes8120377"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12035-013-8394-x","article-title":"alpha-Synuclein and mitochondrial dysfunction in Parkinson\u2019s disease","volume":"47","author":"Mullin","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"ref_56","unstructured":"Belaidi, A.A., and Bush, A.I. (2015). Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: Targets for therapeutics. J. Neurochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mito.2015.02.001","article-title":"Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders","volume":"21","author":"Mena","year":"2015","journal-title":"Mitochondrion"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbamcr.2016.12.002","article-title":"Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms","volume":"1864","author":"Eid","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","article-title":"Iron-overload cardiomyopathy: Pathophysiology, diagnosis, and treatment","volume":"16","author":"Murphy","year":"2010","journal-title":"J. Card. Fail."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fisher, S.A., Brunskill, S.J., Doree, C., Chowdhury, O., Gooding, S., and Roberts, D.J. (2013). Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004839.pub3"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/CRD.0b013e3182a67805","article-title":"Cardiac involvement in hemochromatosis","volume":"22","author":"Gulati","year":"2014","journal-title":"Cardiol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/17474124.2016.1119043","article-title":"Optimizing the diagnosis and the treatment of iron overload diseases","volume":"10","author":"Brissot","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2017.1318052","article-title":"Deferiprone for the treatment of transfusional iron overload in thalassemia","volume":"10","author":"Belmont","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_64","first-page":"Cd007476","article-title":"Deferasirox for managing iron overload in people with thalassaemia","volume":"8","author":"Bollig","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.hoc.2017.12.002","article-title":"Iron Chelation Therapy as a Modality of Management","volume":"32","author":"Aydinok","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/HCO.0000000000000511","article-title":"Iron overload cardiomyopathy: From diagnosis to management","volume":"33","year":"2018","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ballas, S.K., Zeidan, A.M., Duong, V.H., DeVeaux, M., and Heeney, M.M. (2018). The effect of iron chelation therapy on overall survival in sickle cell disease and beta-thalassemia: A systematic review. Am. J. Hematol.","DOI":"10.1002\/ajh.25103"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtemb.2014.12.012","article-title":"Neurodegenerative diseases and therapeutic strategies using iron chelators","volume":"31","author":"Ward","year":"2015","journal-title":"J. Trace Elem. Med. Boil."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Dusek, P., Schneider, S.A., and Aaseth, J. (2016). Iron chelation in the treatment of neurodegenerative diseases. J. Trace Elem. Med. Boil.","DOI":"10.1016\/j.jtemb.2016.03.010"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"C1383","DOI":"10.1152\/ajpcell.00054.2007","article-title":"Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: Biological and clinical implications","volume":"293","author":"Shvartsman","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Grolez, G., Moreau, C., Sablonniere, B., Garcon, G., Devedjian, J.C., Meguig, S., Gele, P., Delmaire, C., Bordet, R., and Defebvre, L. (2015). Ceruloplasmin activity and iron chelation treatment of patients with Parkinson\u2019s disease. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0331-3"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Ward","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2008-1040847","article-title":"Friedreich\u2019s ataxia: Clinical aspects and pathogenesis","volume":"19","author":"Pandolfo","year":"1999","journal-title":"Semin. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0387-7604(00)00175-3","article-title":"Friedreich\u2019s ataxia and iron metabolism","volume":"22","author":"Gordon","year":"2000","journal-title":"Brain Dev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: Ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/13543784.12.2.235","article-title":"Friedreich\u2019s ataxia: Iron chelators that target the mitochondrion as a therapeutic strategy?","volume":"12","author":"Richardson","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: Biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jnc.12300","article-title":"Deferiprone for the treatment of Friedreich\u2019s ataxia","volume":"126","author":"Pandolfo","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12311-010-0212-7","article-title":"Combined therapy with idebenone and deferiprone in patients with Friedreich\u2019s ataxia","volume":"10","author":"Aracil","year":"2011","journal-title":"Cerebellum"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0883073816636087","article-title":"Clinical Experience With Deferiprone Treatment for Friedreich Ataxia","volume":"31","author":"Glik","year":"2016","journal-title":"J. Child Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: A 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ane.12141","article-title":"Triple therapy with deferiprone, idebenone and riboflavin in Friedreich\u2019s ataxia\u2014Open-label trial","volume":"129","author":"Arpa","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1590\/0004-282X20160102","article-title":"Neurodegeneration with brain iron accumulation","volume":"74","author":"Limongi","year":"2016","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-genom-090314-025011","article-title":"Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms","volume":"16","author":"Meyer","year":"2015","journal-title":"Annu. Rev Genom. Hum. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1590\/0004-282X20160080","article-title":"A diagnostic approach for neurodegeneration with brain iron accumulation: Clinical features, genetics and brain imaging","volume":"74","author":"Salomao","year":"2016","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"ref_87","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (2018). Pantothenate Kinase-Associated Neurodegeneration. Genereviews((R)), University of Washington."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.1977.00500240017003","article-title":"Hallervorden-Spatz syndrome","volume":"34","author":"Vakili","year":"1977","journal-title":"Arch. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.39.3.440","article-title":"Magnetic resonance imaging in pathologically proven Hallervorden-Spatz disease","volume":"39","author":"Schaffert","year":"1989","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0887-8994(01)00269-7","article-title":"Iron in the Hallervorden-Spatz syndrome","volume":"25","author":"Koeppen","year":"2001","journal-title":"Pediatr. Neurol."},{"key":"ref_91","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (1993). PLA2G6-Associated Neurodegeneration. Genereviews((R)), University of Washington."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-410502-7.00003-X","article-title":"Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): Review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes","volume":"110","author":"Kurian","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-2007-973482","article-title":"Neuroaxonal dystrophy with dystonia and pallidal involvement","volume":"30","author":"Simonati","year":"1999","journal-title":"Neuropediatrics"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s004010050049","article-title":"Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology","volume":"99","author":"Wakabayashi","year":"2000","journal-title":"Acta Neuropathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1212\/WNL.0b013e31827e07be","article-title":"New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN","volume":"80","author":"Hogarth","year":"2013","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.25256","article-title":"Mitochondrial membrane protein associated neurodegenration: A novel variant of neurodegeneration with brain iron accumulation","volume":"28","author":"Schulte","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-410502-7.00004-1","article-title":"Mitochondrial membrane protein-associated neurodegeneration (MPAN)","volume":"110","author":"Hartig","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.03.014","article-title":"Mitochondrial membrane protein-associated neurodegeneration","volume":"39","author":"Deutschlander","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/B978-0-12-410502-7.00005-3","article-title":"BPAN: The only X-linked dominant NBIA disorder","volume":"110","author":"Haack","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.parkreldis.2013.11.019","article-title":"Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: Novel mutations and neuropsychiatric phenotype in three adult patients","volume":"20","author":"Verhoeven","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Evers, C., Seitz, A., Assmann, B., Opladen, T., Karch, S., Hinderhofer, K., Granzow, M., Paramasivam, N., Eils, R., and Diessl, N. (2017). Diagnosis of CoPAN by whole exome sequencing: Waking up a sleeping tiger\u2019s eye. Am. J. Med. Genet. Part A.","DOI":"10.1002\/ajmg.a.38252"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.parkreldis.2016.03.011","article-title":"Mutational analysis of COASY in an Italian patient with NBIA","volume":"28","author":"Annesi","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajhg.2013.11.008","article-title":"Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation","volume":"94","author":"Dusi","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.22122","article-title":"Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA)","volume":"68","author":"Kruer","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1469-8749.2011.03993.x","article-title":"FA2H-related disorders: A novel c.270+3A>T splice-site mutation leads to a complex neurodegenerative phenotype","volume":"53","author":"Garone","year":"2011","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_106","first-page":"347","article-title":"Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome","volume":"89","author":"Wriekat","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/ng1884","article-title":"Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase","volume":"38","author":"Ramirez","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/mds.22947","article-title":"ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation","volume":"25","author":"Schneider","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0022-510X(98)00015-X","article-title":"A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis","volume":"156","author":"Yazaki","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/shem.2002.35633","article-title":"The copper-iron connection: Hereditary aceruloplasminemia","volume":"39","author":"Nittis","year":"2002","journal-title":"Semin. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ng571","article-title":"Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease","volume":"28","author":"Curtis","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2015.02.007","article-title":"Neuroferritinopathy: From ferritin structure modification to pathogenetic mechanism","volume":"81","author":"Levi","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000310985.40011.d6","article-title":"T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation","volume":"70","author":"McNeill","year":"2008","journal-title":"Neurology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/1817-1745.97618","article-title":"Magnetic resonance imaging in pantothenate kinase-2-associated neurodegeneration","volume":"7","author":"Singh","year":"2012","journal-title":"J. Pediatr. Neurosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","article-title":"Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up","volume":"20","author":"Cossu","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_118","first-page":"7279","article-title":"A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients","volume":"9","author":"Rohani","year":"2017","journal-title":"Neurol. Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","article-title":"Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"14","author":"Investigators","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer\u2019s disease: A phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1309\/LMF28S2GIMXNWHMM","article-title":"The molecular biology of human iron metabolism","volume":"45","author":"Winter","year":"2014","journal-title":"Lab. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14740330903535845","article-title":"Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases","volume":"9","author":"Kontoghiorghes","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-291X(90)90498-C","article-title":"1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles","volume":"170","author":"Hasegawa","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01957472","article-title":"Latent iron deficiency alters gamma-aminobutyric acid and glutamate metabolism in rat brain","volume":"45","author":"Shukla","year":"1989","journal-title":"Experientia"},{"key":"ref_126","first-page":"215","article-title":"Effects of iron deficiency on iron distribution and gamma-aminobutyric acid (GABA) metabolism in young rat brain tissues","volume":"73","author":"Li","year":"1998","journal-title":"Hokkaido Igaku Zasshi"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fneur.2017.00385","article-title":"Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy","volume":"8","author":"Fonderico","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2010-1390","article-title":"PBT2 rapidly improves cognition in Alzheimer\u2019s Disease: Additional phase II analyses","volume":"20","author":"Faux","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/nyas.13088","article-title":"Current recommendations for chelation for transfusion-dependent thalassemia","volume":"1368","author":"Kwiatkowski","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199717060-00006","article-title":"A risk-benefit assessment of iron-chelation therapy","volume":"17","author":"Porter","year":"1997","journal-title":"Drug Saf."},{"key":"ref_131","first-page":"795","article-title":"Deferiprone in the treatment of transfusion-dependent thalassemia: A review and perspective","volume":"3","author":"Galanello","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/blood-2007-02-065805","article-title":"Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia","volume":"109","author":"Henter","year":"2007","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12833","article-title":"Safety profiles of iron chelators in young patients with haemoglobinopathies","volume":"98","author":"Botzenhardt","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jcp.47.7.657","article-title":"Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine","volume":"47","author":"Wonke","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Crisponi, G., Nurchi, V.M., Crespo-Alonso, M., Sanna, G., Zoroddu, M.A., Alberti, G., and Biesuz, R. (2015). A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133050"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.2741\/3575","article-title":"Molecular mechanisms of copper homeostasis","volume":"14","author":"Lalioti","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.284.5415.805","article-title":"Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase","volume":"284","author":"Rae","year":"1999","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/jps.21183","article-title":"Past, present, and future technologies for oral delivery of therapeutic proteins","volume":"97","author":"Singh","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: Death by Lipid Peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Boil."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.biocel.2015.01.018","article-title":"Mitochondria: A crossroads for lipid metabolism defect in neurodegeneration with brain iron accumulation diseases","volume":"63","author":"Aoun","year":"2015","journal-title":"Int. J. Biochem. Cell Boil."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2014.00038","article-title":"The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders","volume":"5","author":"Urrutia","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","article-title":"Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications","volume":"111","author":"Sohn","year":"2008","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2001.00490.x","article-title":"Green tea polyphenol (\u2212)-epigallocatechin-3- gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration","volume":"78","author":"Levites","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1385\/JMN:24:3:401","article-title":"Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: Effect of neuroprotective drugs R-apomorphine and green tea polyphenol (\u2212)-epigallocatechin-3-gallate","volume":"24","author":"Mandel","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0024-3205(02)02347-0","article-title":"Effects of green tea polyphenols on dopamine uptake and on MPP+-induced dopamine neuron injury","volume":"72","author":"Pan","year":"2003","journal-title":"Life Sci."},{"key":"ref_149","first-page":"376","article-title":"Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation","volume":"26","author":"Li","year":"2006","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","article-title":"Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys","volume":"286","author":"Chen","year":"2015","journal-title":"Neuroscience"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","article-title":"Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and other neurodegenerative diseases","volume":"13","author":"Zheng","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuroscience.2011.03.040","article-title":"Novel molecular targets of the neuroprotective\/neurorescue multimodal iron chelating drug M30 in the mouse brain","volume":"189","author":"Kupershmidt","year":"2011","journal-title":"Neuroscience"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12035-012-8304-7","article-title":"Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer\u2019s-like neuropathology and age-related alterations in mice","volume":"46","author":"Kupershmidt","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.neurobiolaging.2014.10.026","article-title":"Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A\/monoamine oxidase-B inhibitor in animal models of Parkinson\u2019s disease and aging","volume":"36","author":"Amit","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1021\/ja068965r","article-title":"Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer\u2019s therapy","volume":"129","author":"Storr","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1021\/jm701225u","article-title":"Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer\u2019s disease","volume":"50","author":"Bolognesi","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1021\/jm100329q","article-title":"Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties","volume":"53","author":"Perez","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1016\/j.bmc.2012.07.045","article-title":"O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation","volume":"20","author":"Mao","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2018.02.023","article-title":"Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer\u2019s disease","volume":"148","author":"Hiremathad","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jinorgbio.2016.05.001","article-title":"Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer\u2019s disease using multifunctional tacrine-coumarin hybrid molecules","volume":"161","author":"Hamulakova","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm901618d","article-title":"Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2\/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson\u2019s disease","volume":"53","author":"Ghosh","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/acschemneuro.6b00356","article-title":"A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson\u2019s Disease","volume":"8","author":"Das","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2017.05.019","article-title":"A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses alpha-syn- and MPTP-induced toxicities in vivo","volume":"123","author":"Das","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1016\/j.bmc.2011.07.033","article-title":"Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"19","author":"Chen","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.1021\/jm300978h","article-title":"Multitarget-directed benzylideneindanone derivatives: Anti-beta-amyloid (Abeta) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer\u2019s disease","volume":"55","author":"Huang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1039\/c3dt50406a","article-title":"Multifunctional iron-chelators with protective roles against neurodegenerative diseases","volume":"42","author":"Nunes","year":"2013","journal-title":"Dalton Trans."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.bmc.2015.04.009","article-title":"Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer\u2019s disease","volume":"23","author":"Xie","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/acschemneuro.5b00224","article-title":"Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer\u2019s Disease","volume":"7","author":"Sheng","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/acschemneuro.6b00309","article-title":"Neuroprotective effect of a new 7,8-dihydroxycoumarin-based Fe2+\/Cu2+ chelator in cell and animal models of Parkinson\u2019s disease","volume":"12","author":"Aguirre","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Garcia-Beltran, O., Mena, N.P., Aguirre, P., Barriga-Gonzalez, G., Galdamez, A., Nagles, E., Adasme, T., Hidalgo, C., and Nunez, M.T. (2017). Development of an iron-selective antioxidant probe with protective effects on neuronal function. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189043"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Chen, S.Q., Wang, Z.S., Ma, Y.X., Zhang, W., Lu, J.L., Liang, Y.R., and Zheng, X.Q. (2018). Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases. Molecules, 23.","DOI":"10.3390\/molecules23030512"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF03033171","article-title":"Green tea polyphenol (\u2212)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway","volume":"5","author":"Mandel","year":"2003","journal-title":"Neurotox. Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3945\/jn.117.255034","article-title":"Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease","volume":"147","author":"Xu","year":"2017","journal-title":"J. Nutr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainres.2006.04.071","article-title":"(\u2212)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway","volume":"1097","author":"Li","year":"2006","journal-title":"Brain Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0165-6147(99)01379-6","article-title":"Dopamine transporters and neuronal injury","volume":"20","author":"Miller","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molbrainres.2005.08.014","article-title":"Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons","volume":"141","author":"McKinley","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1046\/j.1471-4159.1997.69031322.x","article-title":"Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter","volume":"69","author":"Gainetdinov","year":"1997","journal-title":"J. Neurochem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/exnr.1998.6995","article-title":"Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter","volume":"155","author":"Bezard","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0891-5849(99)00005-2","article-title":"Scavenging of hydrogen peroxide and inhibition of ultraviolet light-induced oxidative DNA damage by aqueous extracts from green and black teas","volume":"26","author":"Wei","year":"1999","journal-title":"Free. Radic. Boil. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0278-6915(02)00169-2","article-title":"Direct scavenging of nitric oxide and superoxide by green tea","volume":"40","author":"Nakagawa","year":"2002","journal-title":"Food Chem. Toxicol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3275s","DOI":"10.1093\/jn\/133.10.3275S","article-title":"Antioxidant activity of tea polyphenols in vivo: Evidence from animal studies","volume":"133","author":"Frei","year":"2003","journal-title":"J. Nutr."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.taap.2005.01.004","article-title":"Green tea polyphenol epigallocatechin-3-gallate differentially modulates oxidative stress in PC12 cell compartments","volume":"207","author":"Raza","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbrc.2007.08.079","article-title":"Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells","volume":"362","author":"Noda","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1196\/annals.1397.046","article-title":"Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells","volume":"1095","author":"Hsuuw","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-009-0401-4","article-title":"Epigallocatechin-3-gallate induced primary cultures of rat hippocampal neurons death linked to calcium overload and oxidative stress","volume":"379","author":"Yin","year":"2009","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10565-009-9137-7","article-title":"Prooxidative effects of green tea polyphenol (\u2212)-epigallocatechin-3-gallate on the HIT-T15 pancreatic beta cell line","volume":"26","author":"Suh","year":"2010","journal-title":"Cell Boil. Toxicol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/ijms12010742","article-title":"Modulation of Ca(2)(+) signals by epigallocatechin-3-gallate(EGCG) in cultured rat hippocampal neurons","volume":"12","author":"Wang","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/carcin\/bgi040","article-title":"Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells","volume":"26","author":"Qanungo","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref_189","first-page":"533","article-title":"Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells","volume":"17","author":"Cavet","year":"2011","journal-title":"Mol. Vis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0043-114865","article-title":"Epigallocatechin-3-Gallate Protects against Homocysteine-Induced Brain Damage in Rats","volume":"84","author":"Wang","year":"2018","journal-title":"Planta Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.pneurobio.2007.06.001","article-title":"Iron dysregulation in Alzheimer\u2019s disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents","volume":"82","author":"Mandel","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuroscience.2017.01.025","article-title":"Involvement of PKCalpha and ERK1\/2 signaling pathways in EGCG\u2019s protection against stress-induced neural injuries in Wistar rats","volume":"346","author":"Zhao","year":"2017","journal-title":"Neuroscience"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuropharm.2017.05.026","article-title":"The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer\u2019s disease models","volume":"123","author":"Amit","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2174\/156720510791162403","article-title":"Up-regulation of hypoxia-inducible factor (HIF)-1\u03b1 and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30","volume":"7","author":"Amit","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jcb.21588","article-title":"Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha\/2alpha is mediated through chelation of iron","volume":"103","author":"Park","year":"2008","journal-title":"J. Cell Biochem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12640-016-9677-6","article-title":"A novel iron chelator-radical scavenger ameliorates motor dysfunction and improves life span and mitochondrial biogenesis in SOD1 G93A ALS mice","volume":"31","author":"Amit","year":"2017","journal-title":"Neurotox. Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12031-016-0763-2","article-title":"Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1 G93A Transgenic ALS Mice","volume":"59","author":"Amit","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.brainresrev.2005.03.002","article-title":"Glucose transport to the brain: A systems model","volume":"49","author":"Qutub","year":"2005","journal-title":"Brain Res. Rev."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/anie.200603866","article-title":"Combating Alzheimer\u2019s disease with multifunctional molecules designed for metal passivation","volume":"46","author":"Schugar","year":"2007","journal-title":"Angew. Chem."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/cercor\/bhs309","article-title":"Higher transport and metabolism of glucose in astrocytes compared with neurons: A multiphoton study of hippocampal and cerebellar tissue slices","volume":"24","author":"Jakoby","year":"2014","journal-title":"Cereb. Cortex"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","article-title":"Tacrine derivatives and Alzheimer\u2019s disease","volume":"17","author":"Tumiatti","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2302\/kjm.36.381","article-title":"Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease","volume":"36","author":"Giacobini","year":"1987","journal-title":"Keio J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/WAD.0b013e318157205b","article-title":"Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting","volume":"22","author":"Jogani","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/4\/109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:26:36Z","timestamp":1760196396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/11\/4\/109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":204,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["ph11040109"],"URL":"https:\/\/doi.org\/10.3390\/ph11040109","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]}}}